Clinical trials: Bendamustine
Recurrent Small Cell Lung Cancer
Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)
Determination of response rate Assessment of toxicity and determination of "time to progression"
- Trial name
- NCT00168922
- Testing
- Bendamustin/Ribomustin
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Charite University, Berlin, Germany
Refractory or Relapsed Diffuse Large B Cell Lymphoma
A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma
This is a prospective, multicenter, single-arm, open phase II study to explore the efficacy and safety of Zanubrutinib in combination with Polatuzumab Vedotin, bendamustine, and rituximab (Polo-ZBR) in subjects with…
- Trial name
- NCT06554600
- Testing
- Zanubrutinib, Polatuzumab Vedotin, Bendamustine
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Chronic Lymphocytic Leukemia
A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic Leukemia
This is a prospective, multicenter, open label, non-randomized, phase I/II-study to define safety and efficacy of BRL combination in relapsed/refractory patients and to recommend a safe and efficacious dose for future phase…
- Trial name
- CLL2P (NCT01558167)
- Testing
- Bendamustine, Rituximab, Lenalidomide
- Where
- Germany
- Volunteers
- 22 people
- Sponsor
- German CLL Study Group
Chronic Lymphocytic Leukemia
Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia
RATIONALE: Monoclonal antibodies, such as alemtuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00634881
- Testing
- Alemtuzumab i.v., Alemtuzumab s.c.
- Where
- 6 sites in Germany
- Volunteers
- 13 people
- Sponsor
- German CLL Study Group
Multiple Myeloma
Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma
The purpose of this study is to improve efficacy of treatment for patients with newly diagnosed multiple myeloma who are not eligible for high-dose chemotherapy followed by autologous stem cell transplantation by Bendamustin…
- Trial name
- BPV (NCT02237261)
- Testing
- Bendamustine, Bortezomib, Prednisone
- Where
- 15 sites in Germany
- Volunteers
- 46 people
- Sponsor
- University Hospital Heidelberg
Lymphoma, Mantle-Cell
Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL
A Czech Lymphoma Study Group, phase II, open-label, study of polatuzumab-vedotin in combination with bendamustine and rituximab for patients with mantle cell lymphoma, who relapse after previous therapy with Bruton tyrosine…
- Trial name
- CLSGMCLPOLA (NCT04913103)
- Testing
- Polatuzumab vedotin, Bendamustine Hydrochloride, Rituximab
- Where
- 7 sites in Czechia
- Volunteers
- 21 people
- Sponsor
- Czech Lymphoma Study Group
Chronic Lymphocytic Leukemia
A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL
This is a prospective multicenter phase 2 study designed with the purpose to evaluate the response rate and safety of treatment with FCR/BR alternating with ibrutinib in treatment-naive patients with chronic lymphocytic leukemia.
- Trial name
- BDHCLL001 (NCT03980002)
- Testing
- FCR and Ibrutinib, BR and Ibrutinib, Ibrutinib and Thalidomide
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
This is a phase 3, open-label, randomized, multi-center study assessing the efficacy and safety of DZD8586 versus investigator's choice in participants with chronic lymphocytic leukemia/small lymphocytic lymphoma who have…
- Trial name
- NCT07139873
- Testing
- DZD8586, Bendamustine, Idelalisib
- Where
- 2 sites in China
- Volunteers
- 250 people
- Sponsor
- Dizal Pharmaceuticals
Lymphoma, Follicular
A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
The purpose of this study is to assess the efficacy and safety of golcadomide in combination with rituximab in participants with newly diagnosed advanced stage Follicular Lymphoma (FL).
- Trial name
- GOLSEEK-2 (NCT06425302)
- Testing
- Golcadomide, Rituximab, Cyclophosphamide
- Where
- 56 sites in United States, Australia and 11 more
- Volunteers
- 95 people
- Sponsor
- Celgene
Non-hodgkin Lymphoma,B Cell
Azacytidine, Bendamustine, Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's Lymphoma
This is an open label, single arm, phase I/II for patients with r/r Non-Hodgkin's Lymphoma . The purpose is to evaluate the safety and efficacy of the combination with Azacytidine, Bendamustine and Piamprizumab
- Trial name
- NCT04897477
- Testing
- Azacytidine, Bendamustine and Piamprizumab
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Hairy Cell Leukemia
Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
Background: Researchers are attempting to develop new treatments for hairy cell leukemia (HCL) that has not responded well to or has recurred after standard HCL therapies.
- Trial name
- NCT01059786
- Testing
- Pentostatin, Rituximab, Bendamustine
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- National Cancer Institute (NCI)
Follicular Lymphoma
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
The purpose of this study is to evaluate the effect of the combined treatment of lenalidomide and rituximab in controlling the Follicular Lymphoma disease and also increase the length of response compared to the available…
- Trial name
- RELEVANCE (NCT01476787)
- Testing
- Rituximab, Lenalidomide, Rituximab-CHOP
- Where
- 36 sites in United States, Japan
- Volunteers
- 1,030 people
- Sponsor
- Celgene
Metastatic Breast Cancer
A Multicentre Phase I-II Study to Investigate the Combination of Bendamustine With Weekly Paclitaxel as First or Second Line Therapy in Patients With Metastatic Breast Cancer
The aim of the study is to establish a feasible combination of bendamustine and paclitaxel in a weekly schedule. The two agents have different toxicity profiles and are well tolerated when given in a weekly fashion.
- Trial name
- RiTa (NCT00661739)
- Testing
- Bendamustine
- Volunteers
- 38 people
- Sponsor
- GBG Forschungs GmbH
Indolent Non-follicular, Non-Hodgkin's Lymphoma
A Phase II Study for Patients With Indolent Non-follicular Non-Hodgkin's Lymphoma
This is a prospective, multicenter phase II trial designed to determine efficacy and safety of a chemoimmunotherapy with the combination of Bendamustine + Rituximab in patients with advanced untreated Indolent non Follicular…
- Trial name
- IIL INFL09 (NCT01929265)
- Testing
- Bendamustine
- Where
- 25 sites in Italy
- Volunteers
- 73 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
This phase I trial evaluates the side effects and best dose of mesothelin-specific T-cells (FH-TCR-Tᴍsʟɴ) in treating patients with pancreatic ductal adenocarcinoma that has spread to other places in the body (metastatic).
- Trial name
- NCT04809766
- Testing
- Autologous Mesothelin-specific TCR-T Cells, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Fred Hutchinson Cancer Center
Lymphoma
A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients
This study is testing a combination of chemo-immuno therapy called RBM. RBM consists of combination of drugs: rituximab, bendamustine, and melphalan followed by reinfusion of the participants own stem cells which is called…
- Trial name
- NCT03352765
- Testing
- rituximab, bendamustine, melphalan
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Relapsed/Refractory Follicular Lymphoma
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
The goal of this clinical study is test how well the study drug, axicabtagene ciloleucel, works in participants with relapsed/refractory follicular lymphoma
- Trial name
- ZUMA-22 (NCT05371093)
- Testing
- Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine
- Where
- 52 sites in United States, France and 5 more
- Volunteers
- 231 people
- Sponsor
- Kite, A Gilead Company
Lymphoma
A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
This study is a multicenter, open-label study of polatuzumab vedotin administered by intravenous (IV) infusion in combination with standard doses of bendamustine (B) and rituximab (R) or obinutuzumab (G) in participants with…
- Trial name
- NCT02257567
- Testing
- Bendamustine, Obinutuzumab, Polatuzumab vedotin (Liquid)
- Where
- 62 sites in United States, Australia and 11 more
- Volunteers
- 331 people
- Sponsor
- Hoffmann-La Roche
Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL
To investigate the tolerability and safety of OPB-111077 in combination with bendamustine and rituximab in patients with r/r DLBCL.
- Trial name
- NCT04049825
- Testing
- OPB-111077
- Where
- Japan
- Volunteers
- 36 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Chronic Lymphocytic Leukemia
Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL)
Many chemotherapy combinations may be used to treat patients with chronic lymphocytic leukemia (CLL). Although there are many options, a single, best option is not agreed upon by most cancer specialists.
- Trial name
- NCT00758693
- Testing
- Bendamustine, Rituximab
- Where
- United States
- Sponsor
- University of Kentucky